Technology ID

Method for Inducing T-Cell Proliferation

Leonard, Warren
Therapeutic Areas
Infectious Disease
Development Status
In vivo data available (animal)
Lead IC
This technology relates to the use of thymic stromal lymphopoietin (TSLP) to induce CD4+ T cell proliferation. This proliferation could be of particular relevance for patients in whom this cell population has been significantly reduced by HIV/AIDS or other conditions resulting in immunodeficiency. The proliferation of isolated CD4+ T cells can be induced through direct contact with TSLP or a nucleic acid encoding TSLP. The patent application also describes methods of inducing or enhancing an immune response through administration of CD4+ T cells that have been isolated and induced to proliferate using TSLP or a nucleic acid encoding TSLP. TSLPR knockout mice are also described in the patent application and available for licensing through a biological materials license agreement.
Commercial Applications
  • Immunotherapy
Licensing Contact:
Kolesnitchenko, Vincent